Trial Profile
A Phase II Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects: Controlled, Parallel, Multicenter
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Adipose stem cell therapy Anterogen (Primary)
- Indications Burns
- Focus Therapeutic Use
- Sponsors Anterogen
- 23 Aug 2023 Status changed from active, no longer recruiting to completed.
- 19 Jul 2021 Planned End Date changed from 1 Jul 2021 to 1 Jun 2023.
- 19 Jul 2021 Planned primary completion date changed from 1 May 2021 to 1 Dec 2022.